- $495.69m
- $403.02m
U.S. STOCKS ON THE MOVE-Hawkins, Netflix, Alibaba Group
Cabaletta Bio climbs after pricing share offering
Brief: Cabaletta Bio Announces Pricing Of Public Offering Of Common Stock
Brief: Cabaletta Bio Announces Proposed Public Offering Of Common Stock
U.S. STOCKS ON THE MOVE-Applied Digital, Amdocs, First Watch
U.S. STOCKS ON THE MOVE-Shake Shack, Western Alliance, Blue Apron
Cabaletta up on FDA nod for trial on treatment for rare conditions
Cabaletta Bio rises on FDA clearance to start trial for treatment for rare conditions
Brief: Cabaletta Bio Receives FDA Clearance Of Ind Application For Caba-201 For Treatment Of Myositis
Brief: Cabaletta Bio Reports Q1 2023 Financial Results And Provides Business Update
Cabaletta Bio Inc reports results for the quarter ended in March - Earnings Summary
Cabaletta Bio Inc expected to post a loss of 48 cents a share - Earnings Preview
Brief: Cabaletta Bio Receives FDA Fast Track Designation For CABA-201
Cabaletta Bio rises on FDA nod for human trials of lupus treatment
U.S. STOCKS ON THE MOVE-Micron Technology, Chicken Soup for the Soul Entertainment, Braze
Cabaletta Bio rises on FDA nod for human trials of lupus treatment
Brief: Cabaletta Bio Receives FDA Clearance Of Ind Application For Caba-201 For Treatment Of Systemic Lupus Erythematosus
Brief: Cabaletta Bio Files For Mixed Shelf Of Up To $350 Mln – SEC Filing
Cabaletta Bio Inc reports results for the quarter ended in December - Earnings Summary